Taro Pharmaceutical Industries (NYSE:TARO – Get Rating) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright cut their price objective on Taro Pharmaceutical Industries from $54.00 to $35.00 and set a “buy” rating on the […]